Symphony Allegro

Symphony Allegro, formed through a collaboration between Symphony Capital Partners and Alexza Pharmaceuticals, is dedicated to the development of Alexza's AZ-002 Staccato Alprazolam and AZ-004 Staccato Loxapine programs. It supports AZ-002 through Phase II clinical trials for the treatment of panic attacks in patients with panic disorder and supports AZ-004 through Phase II clinical trials for the treatment of acute agitation in patients with schizophrenia.